Novel Bispecific Antibody Shows Promise Against Aggressive Blood Cancers
A new bispecific antibody therapy, AFM28, has shown strong preclinical results in targeting treatment-resistant cells in acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), according to new research.